Denise L. Loring

Retired Partner

  • JD, New York University School of Law, 1982
  • MS (Molecular Biology), Albert Einstein College of Medicine of Yeshiva University, 1978
  • BS (Biological Sciences), with Honors, Stony Brook University, 1976


  • New York
  • U.S. Patent and Trademark Office

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Southern District of New York
  • American Bar Association
  • American Intellectual Property Law Association
  • Federal Circuit Bar Association
  • New York Intellectual Property Law Association
  • The Best Lawyers in America (2010-2014, 2016)
  • Managing IP – “IP Star” (2013-2014)
  • Guide to the World’s Leading Women in Business Law (2014)
  • New York Super Lawyers (2006-2015)
  • LMG Life Sciences: “Life Sciences Star” (2013)
  • IAM 250: “World’s Leading Patent Litigators" (2011-2012)
  • Euromoney's Guide to the World's Leading Patent Law Experts (1999-2013)
  • PLC Which Lawyer? (2012)
  • LMG Life Sciences: “Life Sciences Star” (2012)
  • IAM Patent 1000 – The World's Leading Patent Practitioners (2013-2015)

Denise L. Loring

Retired Partner

Denise Loring has extensive experience as lead counsel in high-stakes patent litigation, in both U.S. federal and international courts. Denise’s practice included a variety of technologies, but focused particularly on biotech and pharmaceutical litigation, including ANDA litigation representing innovator companies. Denise’s educational training in molecular biology and 30 years of practice are reflected in her track record, from planning a winning strategy, to succeeding at both the trial and appellate level. Denise has represented major pharmaceutical and biotech companies, including AstraZeneca, Genzyme, Pfizer, and Purdue Pharma. Denise is also a frequent lecturer and has spoken recently on topics that include biosimilars legislation, patent eligibility of diagnostic methods patents and isolated DNA sequences, the proposed patent reform legislation and the use of demonstrative exhibits and graphics in expert testimony at trial.


  • Shelbyzyme v. Genzyme (D. Del.). Denise was lead counsel in this biotech case defending Genzyme's life-saving drug, Fabrazyme®, against charges of patent infringement.
  • AstraZeneca v. Apotex (D. NJ). In 2009, Denise and her team obtained a preliminary injunction, barring a generic drug company from an at-risk launch of a generic version of our client’s pediatric asthma drug. 
  • AstraZeneca v. Ivax (D. NJ). In this case involving inhalation medication for the treatment of asthma, the District Court granted a motion brought by Denise and her team for a temporary restraining order. The case settled favorably before commencement of a preliminary injunction hearing. 
  • AstraZeneca v. Mayne Pharma (S.D.N.Y.). Denise was lead counsel in this case involving an injectable emulsion anesthetic. The District Court entered judgment for our client that its patents were valid, enforceable and infringed after a two-week bench trial in March 2005. The Federal Circuit affirmed. 
  • Cancer Research Technology Limited and Schering Corp. v. Barr (D. Del.). In this case involving medication for the treatment of malignant glioma, the District Court entered judgment for Barr; the Federal Circuit reversed, confirming the validity and enforceability of out clients’ patent. 
  • Purdue v. Endo (S.D.N.Y.). This case involved patents on Purdue’s OxyContin® controlled-release pain medication. An eleven-day bench trial resulted in judgment that Purdue’s patents were infringed, but unenforceable. On appeal, the Federal Circuit reversed the judgment of unenforceability and affirmed infringement. The case settled favorably.  
  • Wyeth v. Sandoz (D. Del.). Denise represented Wyeth in this pending ANDA case involving antibiotic compounds and compositions.

Selected Media


  • Contributor, “US Patent Litigation 150 Questions & Answers,” Published by AIPPI, Japan
Cookie Settings